SCHEMBL4352806

SCHEMBL4352806

O=C1N=C(N2CCSCC2)SC1=Cc1ccc(Cl)cc1

nearest known ligand 0.79

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 2/20 0.70
MAPT P10636 2/20 0.61
HTT P42858 1/20 0.60
ALDH1A1 P00352 2/20 0.60
RAB9A P51151 2/20 0.60
AVPR1A P37288 1/20 0.58
MEN1 O00255 5/20 0.57
KMT2A Q03164 5/20 0.57
MAPK1 P28482 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
NPC1 O15118 2/20 0.56
ALOX5 P09917 1/20 0.56
IDE P14735 1/20 0.56
DCTPP1 Q9H773 1/20 0.55
GRIN1 Q05586 3/20 0.53
GRIN2B Q13224 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4352805 1.00 ENPP2 (0.70) ENPP2MAPTHTTALDH1A1RAB9A
SCHEMBL4350822 0.89 MAPT (0.76) ENPP2MAPTHTTALDH1A1RAB9A
SCHEMBL4350820 0.89 MAPT (0.76) ENPP2MAPTHTTALDH1A1RAB9A
SCHEMBL4357176 0.88 RAB9A (0.76) ENPP2MAPTHTTALDH1A1RAB9A
Bromide SCHEMBL4352356 0.88 MAPT (0.74) ENPP2MAPTHTTALDH1A1RAB9A
Bromide SCHEMBL4352358 0.88 MAPT (0.74) ENPP2MAPTHTTALDH1A1RAB9A
SCHEMBL4357174 0.88 RAB9A (0.76) ENPP2MAPTHTTALDH1A1RAB9A
SCHEMBL4355588 0.87 MAPT (0.61) ENPP2MAPTHTTALDH1A1RAB9A
SCHEMBL4351505 0.87 MAPT (0.81) ENPP2MAPTHTTALDH1A1RAB9A
SCHEMBL4351510 0.87 MAPT (0.81) ENPP2MAPTHTTALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP claimed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 ENPP2 1946/4885MAPT 1470/4885HTT 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.